Compare Global X Uranium ETF (URA) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Uranium ETF vs Vertex Pharmaceuticals Incorporated — how do they compare? Global X Uranium ETF trades at $38.9 (market cap $5.48B), while Vertex Pharmaceuticals Incorporated trades at $510.08 (market cap $127.55B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 23.3× Global X Uranium ETF's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Global X Uranium ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Uranium ETF for 62 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| URA | VRTX | |
|---|---|---|
Market Cap | $5.48B | $127.55B |
Volume | 5,287,170 | 1,487,944 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $61.81 | $557.96 |
52-Week Low | $37.52 | $407.37 |
Typical Hold Time | 62 Days | 120 Days |
Enterprise Value | — | $121.68B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
URA (Global X Uranium ETF) is trading at $38.56, down 3.43% amid bearish technical signals with 19 sell indicators versus 3 buy signals. The ETF faces pressure despite positive nuclear energy sector news, including government funding commitments and growing AI power demand. Current price sits near key support at $38 with resistance at $39.
The uranium sector shows long-term potential with nuclear energy expansion and AI power needs, but URA faces near-term volatility from commodity price sensitivity and concentrated holdings. Investors should weigh structural supply deficits against technical weakness and sector-specific risks.
Vertex Pharmaceuticals (VRTX) trades at $503.25, down 0.47% on the day, with a bearish technical signal despite strong fundamentals. The company maintains dominant cystic fibrosis market position with 86% gross margins and 35% net income margin. Recent positive Phase 2b data for inaxaplin in kidney disease shows pipeline expansion potential. Revenue grew to $12.0B in 2025 with $3.95B net income, recovering from 2024's loss.
Analyst consensus remains strongly bullish with 84% buy ratings and $573.50 price target, representing 14% upside. Key risks include pipeline execution and competitive pressures. The stock offers growth potential through gene therapy expansion but faces volatility from clinical trial outcomes and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Global X Uranium ETF
URA provides broad exposure to the global uranium industry and nuclear energy sector. Unlike pure-play mining funds, it includes companies involved in nuclear component production and infrastructure, with top 2026 holdings such as Cameco, Oklo, and Uranium Energy Corp.
Read more on URA →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
